Moderna reported positive Phase 3 results for its personalized cancer vaccine mRNA-4157, showing a 44% reduction in melanoma recurrence when used alongside Merck's Keytruda.
The science: The vaccine is custom-built for each patient using their tumor's unique genetic mutations, training the immune system to target cancer cells specifically.
Trial results: - 44% reduction in recurrence vs Keytruda alone - Median follow-up: 3 years - 1,089 patients enrolled across 200 sites globally
Our take: This is the most compelling evidence yet that mRNA technology has a future far beyond COVID vaccines. If approved, it would be the first personalized cancer vaccine — a paradigm shift in oncology. Moderna stock rose 12% on the news.
